Fatty liver disease (MASLD/MASH) trials in Germany

In Germany 23 Also abroad 366

23 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 10 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis
Where
Berlin, Frankfurt am Main, Homburg, Leipzig, Lübeck, Mainz, Würzburg
Age
18 years to 80 years
People
1,650 worldwide
Run by
Akero Therapeutics, Inc
See details and how to joinNCT06215716
Phase 3Not yet taking people in Germany
ELEVATE-LIVER: A Study to Test Whether Survodutide Helps Improve Heart Structure and Function in People With Overweight or Obesity and Fatty Liver Disease
Where
Bad Homburg, Erlangen, Freiburg im Breisgau, Leipzig, Mainz
Age
18 years and over
People
600 worldwide
Run by
Boehringer Ingelheim
See details and how to joinNCT07850063 · EU 2026-527091-88-00
Phase 3Taking people
LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis
Where
Berlin, Bochum, Cologne, Dresden, Erlangen, Frankfurt Am Main, Heidelberg, Homburg, Landshut, Leipzig, Luebeck, Magdeburg, Mainz, Mannheim, Muenster, Tuebingen, Wiesbaden, Wuerzburg
Age
18 years and over
People
1,800 worldwide
Run by
Boehringer Ingelheim
See details and how to joinNCT06632444 · EU 2024-513739-25-00
Phase 3Taking people
LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis
Where
Berlin, Bochum, Cologne, Dresden, Frankfurt Am Main, Heidelberg, Homburg, Landshut, Luebeck, Magdeburg, Mainz, Mannheim, Muenster, Wiesbaden, Wuerzburg
Age
18 years and over
People
1,590 worldwide
Run by
Boehringer Ingelheim
See details and how to joinNCT06632457 · EU 2024-513741-36-00
Phase 3Taking people
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Efruxifermin in Subjects with Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Where
Berlin, Hanover, Homburg, Leipzig, Luebeck
Age
18 years and over
People
205 worldwide
Run by
Akero Therapeutics Inc.
See details and how to join2024-512895-36-00 · EU 2024-512895-36-00
Phase 3Taking people
A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
Where
Chemnitz, Frankfurt Am Main, Freiburg im Breisgau, Hanover, Homburg, Muenster
Age
18 years to 80 years
People
1,350 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT06318169 · EU 2023-509912-27-00
Phase 3Taking people
A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
Where
Chemnitz, Frankfurt Am Main, Freiburg im Breisgau, Hanover, Homburg, Muenster
Age
18 years to 75 years
People
1,800 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT06419374 · EU 2023-510395-31-00
No phaseTaking people
Endohepatology-Based Reclassification of Treatment Indication in High-Risk MASLD
Where
Münster
Age
18 years and over
People
500
Run by
University Hospital Muenster
See details and how to joinNCT07877272
Phase 3Not yet taking people in Germany
A pivotal clinical study to investigate the safety and efficacy of efimosfermin compared with placebo in adult participants with compensated cirrhosis due to Metabolic dysfunction-associated steatohepatitis (MASH)
Where
Berlin, Hamburg, Heidelberg, Homburg, Leipzig, Mainz, Muenster
Age
18 years and over
People
382 worldwide
Run by
Glaxosmithkline Research & Development Limited
See details and how to join2026-525755-82-00 · EU 2026-525755-82-00
Phase 3Not yet taking people in Germany
A study to investigate safety and efficacy of efimosfermin compared with placebo in adult participants with compensated cirrhosis (stage F4 fibrosis) due to MASH (NEBULA-2)
Where
Hamburg, Heidelberg, Homburg, Leipzig, Mainz, Muenster
Age
18 years and over
People
69 worldwide
Run by
Glaxosmithkline Research & Development Limited
See details and how to join2026-525757-37-00 · EU 2026-525757-37-00
Phase 3Taking people
A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
Where
Berlin, Frankfurt am Main, Homburg, Leipzig, Lübeck
Age
18 years to 80 years
People
2,150 worldwide
Run by
Akero Therapeutics, Inc
See details and how to joinNCT06528314
Phase 3Taking people
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
Where
Bad Oeynhausen, Berlin, Brandenburg, Dresden, Düsseldorf, Frankfurt, Hanover, Heidelberg, Homburg, Leipzig, Mainz, Neuruppin
Age
18 years and over
People
4,500 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT07165028 · EU 2025-522674-36-00
Phase 3Taking people
A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH
Where
Berlin, Hamburg, Heidelberg, Homburg, Leipzig, Mainz, Muenster
Age
18 years to 75 years
People
1,250 worldwide
Run by
GlaxoSmithKline
See details and how to joinNCT07221188 · EU 2025-523674-16-00
No phaseTaking people
Acquisition of Cardiac Function Parameters in MRI and Echocardiography in Patients With Ethyltoxic Liver Cirrhosis and Transjugular Intrahepatic Portosystemic Shunt (TIPSS) Placement
Where
Jena
Age
18 years to 99 years
People
80
Run by
Stephanie Gräger
See details and how to joinNCT06814990
No phaseTaking people
Identification of Liver Fibrosis Biomarkers
Where
Mainz
Age
18 years to 75 years
People
575 worldwide
Run by
Roche Diagnostics GmbH
See details and how to joinNCT06819917
No phaseTaking people
Time-restricted Feeding in MASLD
Where
Homburg
Age
18 years to 75 years
People
120
Run by
Universität des Saarlandes
See details and how to joinNCT07530809
Phase 3Taking people
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Efruxifermin in Subjects with Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis
Where
Berlin, Frankfurt Am Main, Homburg, Leipzig, Luebeck, Mainz, Wuerzburg
Age
18 years and over
People
244 worldwide
Run by
Akero Therapeutics Inc.
See details and how to join2023-505141-48-00 · EU 2023-505141-48-00
No phaseNot yet taking people in Germany
Long-term Follow-up to Determine Outcome in Liver Disease (LOVE Study)
Where
Homburg
Age
18 years and over
People
30,000 worldwide
Run by
Universität des Saarlandes
See details and how to joinNCT06907563
No phaseTaking people
Global Research Initiative for Patients Screening on MASH
Where
Homburg, Mainz
Age
18 years to 75 years
People
10,000 worldwide
Run by
Julius Clinical
See details and how to joinNCT05651724
No phaseTaking people
Deep Phenotyping of Peripheral Blood Cells and Circulating Factors in Metabolic Diseases
Where
Dresden
Age
18 years and over
People
180
Run by
Technische Universität Dresden
See details and how to joinNCT06396871
No phaseEnrolling by invitation
Prevalence of Advanced Fibrosis in Patients Living With HIV
Where
Mainz
Age
18 years and over
People
300
Run by
Johannes Gutenberg University Mainz
See details and how to joinNCT04066608
No phaseTaking people
Metabolic Phenotyping and Follow-Up of Patients With and Without Diabetes After New Onset of STEMI
Where
Düsseldorf
Age
18 years to 80 years
People
300
Run by
German Diabetes Center
See details and how to joinNCT05046483
No phaseTaking people
The European NAFLD Registry
Where
Aachen, Berlin, Freiburg im Breisgau, Mainz, Würzburg
Age
18 years to 100 years
People
10,000 worldwide
Run by
Newcastle University
See details and how to joinNCT04442334